Eli Lilly shows GLP-1 weight-loss pill Foundayo can dramatically improve sleep apnea
Foundayo, a daily pill, successfully reduced obstructive sleep apnea, according to clinical trial data
Clinical trial results published in JAMA reveal that daily GLP-1 pill, sold under the brand name Foundayo, effectively reduced the severity of obstructive sleep apnea in obese individuals. The drug, developed by Eli Lilly and already approved for obesity treatment, showed a 43.8% reduction in sleep apnea severity in non-PAP users and a 27.5% reduction in PAP users after 52 weeks of treatment.
Participants also experienced significant weight loss, averaging 28 pounds over the study period. Foundayo's cardiovascular benefits are suggested due to its impact on oxygen levels and blood pressure. Eli Lilly plans to seek FDA approval for Foundayo's treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight by year-end.
Written by urgent.news from Scientific American's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
